1. Home
  2. CCCC vs GCGR Comparison

CCCC vs GCGR Comparison

Compare CCCC & GCGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo C4 Therapeutics Inc.

CCCC

C4 Therapeutics Inc.

HOLD

Current Price

$3.73

Market Cap

404.7M

Sector

Health Care

ML Signal

HOLD

GCGR

General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares

N/A

Current Price

$10.15

Market Cap

469.3M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
CCCC
GCGR
Founded
2015
N/A
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
404.7M
469.3M
IPO Year
2020
2026

Fundamental Metrics

Financial Performance
Metric
CCCC
GCGR
Price
$3.73
$10.15
Analyst Decision
Strong Buy
Analyst Count
6
0
Target Price
$12.20
N/A
AVG Volume (30 Days)
2.6M
55.1K
Earning Date
05-06-2026
N/A
Dividend Yield
N/A
N/A
EPS Growth
16.45
N/A
EPS
N/A
N/A
Revenue
$35,947,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
1.02
N/A
52 Week Low
$1.69
$10.05
52 Week High
$5.17
$10.20

Technical Indicators

Market Signals
Indicator
CCCC
GCGR
Relative Strength Index (RSI) 47.01 57.14
Support Level $3.42 $10.09
Resistance Level $3.91 N/A
Average True Range (ATR) 0.22 0.01
MACD 0.00 -0.00
Stochastic Oscillator 47.46 62.50

Price Performance

Historical Comparison
CCCC
GCGR

About CCCC C4 Therapeutics Inc.

C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.

About GCGR General Catalyst Global Resilience Merger Corp. Class A Ordinary Shares

General Catalyst Global Resilience Merger Corp is a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses.

Share on Social Networks: